Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VTRS
VIATRIS INC.
NASDAQ
$16.34
▼ DOWN 3.26% (-0.55)

KEY STATISTICS

Market Cap$19.03 B
52w High$18.39
52w Low$9.43
Dividend Yield2.72%
FrequencyQuarterly
P/E6.48
Volume6.22M
Shares Out.1.16B

COMPANY

LEADERSHIP

Scott Andrew Smith
CHIEF EXECUTIVE
Scott Andrew Smith

COMPENSATION 2026

Salary$1,448,654
Stock Awards$10,150,013
Incentive Plan Pay$2,973,660
All Other Comp.$701,004
Total$15,273,331

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 17, 1980
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
30,000

PRICE TARGET

Target High$22.00
Target Low$20.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$3.81B
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2003-10-09Forward3:2
2003-01-28Forward3:2
1995-08-16Forward3:2
1992-08-03Forward2:1
1986-08-04Forward3:2
1985-02-19Forward2:1
1984-08-01Forward3:2
1984-03-02Forward3:2
1983-07-01Forward2:1
1981-11-16Forward2:1

PRICE

$16.34 ▼ DOWN 3.26% (−$0.55)
OVERLAYS
$16.40$16.60$16.80$17.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM16.34

About Viatris Inc.

https://www.viatris.com ↗

Viatris Inc. is a global healthcare company offering prescription drugs, generics, biosimilars, and APIs across various therapeutic areas, serving diverse markets with a broad portfolio and strategic collaborations.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT VIATRIS INC. IS KNOWN FOR

Inpefa® (sotagliflozin)
Inpefa® (sotagliflozin)

An oral medication for the treatment of heart failure. As the first and only dual SGLT1/2 inhibitor, its recent launch in early 2026 signifies Viatris' focus on expanding its portfolio with innovative cardiovascular therapies.

COMPETITORS

COMPETITOR
AZN COMPARE
JNJ COMPARE
LLY COMPARE
LXRX COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Brands$2.44B $2.35B ▼$2.33B ▼$2.42B ▲
Generics$1.31B $1.34B ▲$1.18B ▼$1.33B ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
Developed Markets Segment$2.27B $2.26B ▼$2.03B ▼$2.2B ▲
Greater China Segment$615.2M $572.9M ▼$680.1M ▲$713.8M ▲
Emerging Markets Segment$571.8M $565.8M ▼$537.4M ▼$543.8M ▲
Japan Australia and New Zealand Segment$307.3M $306.6M ▼$273.5M ▼$296.2M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
496
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.03% · 37.1M
XWD.TO
0.02% · 15.5M
SPY
0.03% · 14.3M
RSP
0.20% · 11.9M
VETS
0.73% · 8.0M
DUSA
5.19% · 3.9M
SCHM
0.36% · 3.2M
DON
1.33% · 3.2M
AVLV
0.20% · 2.5M
FTXH
3.53% · 2.2M
XDWE.L
0.20% · 1.9M
DFAC
0.06% · 1.7M
FMDE
0.25% · 1.2M
JHMM
0.33% · 1.2M
TMSL
0.62% · 1.1M
GSLC
0.11% · 963.1K
NUSC
0.99% · 865.3K
SEIV
0.76% · 699.3K
PPH
1.12% · 678.2K
AMEM.DE
0.17% · 644.3K
FLQM
0.67% · 628.0K
SYLD
0.93% · 583.1K
RECS
0.16% · 567.8K
BBMC
0.40% · 507.7K
ADPV
4.50% · 485.8K
QMOM
1.80% · 465.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
68.23%
HOLDERS
1,423
TOP 12 OF 1,423 · RANKED BY POSITION SIZE
Vanguard Group Inc
140.3M sh · $1.39B
Fmr LLC
96.7M sh · $1.53B
Blackrock Inc.
92.7M sh · $985.06M
Blackrock, Inc.
86.8M sh · $1.08B
Price T Rowe Associates Inc /Md/
84.1M sh · $832.24M
Davis Selected Advisers
78.2M sh · $1.06B
State Street Corp
55.7M sh · $551.5M
Dimensional Fund Advisors LP
40.0M sh · $498.34M
Rubric Capital Management LP
34.2M sh · $542.6M
Geode Capital Management, LLC
32.8M sh · $520.1M
Ameriprise Financial Inc
27.8M sh · $275.45M
Invesco Ltd.
25.3M sh · $250.51M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2025-11-18
SENATE TRADES
John Fetterman
John Fetterman
Sale
2025-04-22
HOUSE TRADES
Rob Bresnahan
Rob Bresnahan
Sale (Full)
2025-04-08
 Ro Khanna
Ro Khanna
Purchase
2024-11-15

INSIDER TRADES

★
OFFICER: SEE REMARKS
Enrietti Andrew
Sale · 998 shares
2026-08-15
★
OFFICER: SEE REMARKS
Enrietti Andrew
Purchase · 25.1K shares
2026-08-15
★
OFFICER: SEE REMARKS
Enrietti Andrew
Purchase · 999 shares
2026-08-15
★
OFFICER: SEE REMARKS
Enrietti Andrew
Sale · 435 shares
2026-08-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
NEUTRAL 2
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Truist Securities BUY JP Morgan NEUTRAL Piper Sandler NEUTRAL Argus Research BUY

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
ROIV$34.71COMPARE
NBIX$154.06COMPARE
BBIO$76.60COMPARE
BAX$26.13COMPARE
ELAN$24.11COMPARE
IONS$61.05COMPARE
RDY$12.18COMPARE